Related Experiment Videos
Experimental antitumour activity of S 16020-2 in a panel of human tumours
L Kraus-Berthier1, N Guilbaud, M Jan
1Institut de Recherches Servier, Division de Cancérologie expérimentale, Suresnes, France.
Abstract:
The antitumour activity of S 16020-2, a new topoisomerase II inhibitor, was evaluated in comparison with doxorubicin against 13 human tumours, including colon (HT-29, Colo320DM), breast (MCF7, MDAMB-231), ovary (SK-OV-3, A2780, NIH:OVCAR-3), non-small cell lung (NCI-H460, A549, Calu-6, NCI-H125) and small-cell lung (NCI-H69, SCLC6) cancers. S 16020-2 was administered weekly intravenous within a dose range of 20-90 mg/kg for 3 weeks. Antitumour responses were obtained in all the tumour types tested except in the two colon cancers. S 16020-2 produced significant growth delays in nine tumour models and induced regressions of all A549 lung tumours. The antitumour activity of S 16020-2 was superior to that of doxorubicin against the NCI-H460, A549, NCI-H69, SCLC6 and NIH:OVCAR-3 xenografts. These results demonstrate the broad spectrum of antitumour activity of S 16020-2 in a large panel of in vivo experimental models and confirm its interest as a potential agent in the treatment of malignant disease.
Insights
A novel topoisomerase II inhibitor, S 16020-2, demonstrated significant antitumour activity across various human cancers, including lung and ovarian models. Its efficacy surpassed doxorubicin in several xenografts, highlighting its potential in cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Topoisomerase II inhibitors are crucial in cancer therapy.
- Developing novel agents with improved efficacy and broader spectrum is essential.
Purpose of the Study:
- To evaluate the antitumour activity of S 16020-2, a new topoisomerase II inhibitor.
- To compare its efficacy against doxorubicin in a diverse panel of human tumour xenografts.
Main Methods:
- S 16020-2 was administered intravenously weekly at 20-90 mg/kg for 3 weeks.
- Evaluated antitumour responses in 13 human tumour models (colon, breast, ovary, non-small cell lung, small-cell lung).
Main Results:
- S 16020-2 showed antitumour responses in all tested tumour types except colon cancer.
- Significant growth delays were observed in nine models; regressions occurred in A549 lung tumours.
- S 16020-2 outperformed doxorubicin against NCI-H460, A549, NCI-H69, SCLC6, and NIH:OVCAR-3 xenografts.
Conclusions:
- S 16020-2 exhibits broad-spectrum antitumour activity in preclinical models.
- These findings support its potential as a therapeutic agent for various malignant diseases.